A2AAR/HDAC-IN-1 (compound 14c) (30 or 60 mg/kg, IP, twice daily for 9 days) shows potent anti-tumor effects in the mouse MC38 xenograft model.
A2AAR/HDAC-IN-1 (90 mg/kg, bid; 150 mg/kg, qd; Oral gavage, for 15 days) shows weak tumor suppression.
A2AAR/HDAC-IN-1 (5 mg/kg, IV; 20 mg/kg PO or IP; once) shows an overall favorable pharmacokinetic profile.
| Animal Model: |
Male ICR mice (6-8 weeks, ~25 g body weight, MC38 colon cancer model) |
| Dosage: |
30 or 60 mg/kg |
| Administration: |
IP, twice daily for 9 days |
| Result: |
Significantly inhibited tumor growth at a dosage of 30 mg/kg (ip, bid), with a tumor growth inhibition (TGI) rate of 68%. At a dosage of 60 mg/kg, the TGI rate was further increased to 85%. |
| Animal Model: |
Male ICR mice (6-8 weeks, ~25 g body weight, MC38 colon cancer model) |
| Dosage: |
90 mg/kg, bid; 150 mg/kg, qd |
| Administration: |
Oral gavage, twice daily (90 mg/kg) or daily (150 mg/kg), for 15 days |
| Result: |
Showed only weak tumor suppression even at a dose of 90 mg/kg (po, bid), with inhibition rates of 44%. |
| Animal Model: |
Male ICR mice (6-8 weeks, ~25 g body weight) |
| Dosage: |
5 mg/kg (IV) and 20 mg/kg (PO, IP) |
| Administration: |
Orally, IP, or IV; once (Pharmacokinetic Analysis) |
| Result: |
Pharmacokinetic Parameters of A2AAR/HDAC-IN-1 in male ICR mice.
| PK Parameters |
po (20 mg/kg) |
iv (5 mg/kg) |
ip (20 mg/kg) |
| Kel (h-1) |
0.390 ± 0.187 |
1.820 ± 0.300 |
0.844 ± 0.021 |
| t1/2 (h) |
2.24 ± 1.16 |
0.389 ± 0.070 |
0.83 ± 0.02 |
| Tmax (h) |
0.333 ± 0.14 |
|
0.25 ± 0.00 |
| Cmax (ng/mL) |
3417 ± 1639 |
4703 ± 735 |
8411 ± 693 |
| C0 (ng/mL) |
|
6498 ± 1285 |
|
| AUC0-t (ng/mL·h) |
3602 ± 1807 |
2098 ± 143 |
10022 ± 931 |
| CL (mL/min/kg) |
|
39.3 ± 2.3 |
33.5 ± 3.1 |
|
|
| 分子量 |
|
| Formula |
|
| CAS 号 |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 纯度 & 产品资料 |
Data Sheet (533 KB)
产品使用指南 (1538 KB)
|
| 参考文献 |
-
. Zhang J, et al. Dual-acting antitumor agents targeting the A2A adenosine receptor and histone deacetylases: Design and synthesis of 4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine derivatives. Eur J Med Chem. 2022 Jun 5;236:114326.
[Content Brief]
|
-
. Zhang J, et al. Dual-acting antitumor agents targeting the A2A adenosine receptor and histone deacetylases: Design and synthesis of 4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine derivatives. Eur J Med Chem. 2022 Jun 5;236:114326.
A2AAR/HDAC-IN-1 相关分类
-
Cell Cycle/DNA Damage
Epigenetics
GPCR/G Protein
-
HDAC
Adenosine Receptor
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
| |